Stock Scorecard



Stock Summary for LENSAR Inc (LNSR) - $12.30 as of 10/31/2025 8:47:01 PM EST

Total Score

7 out of 30

Safety Score

22 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for LNSR

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for LNSR

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for LNSR

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for LNSR

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for LNSR (22 out of 100)

Stock Price Rating (Max of 10) 5
Historical Stock Price Rating (Max of 10) 4
Stock Price Trend (Max of 10) 10
Book Value (Max of 10) 1
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 0
Analyst Strong Buy Ratings (Max of 5) 0
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 2
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for LNSR

SpyGlass Pharma Appoints Elizabeth O'Farrell to its Board of Directors - Genmab ( NASDAQ:GMAB ) , Geron ( NASDAQ:GERN ) 8/19/2025 12:00:00 PM
LENSAR Reports Second Quarter 2025 Results and Provides Business Update 8/7/2025 11:00:00 AM
LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - LENSAR ( NASDAQ:LNSR ) 7/1/2025 8:01:00 PM
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LNSR, ATAI, ICAD on Behalf of Shareholders - ATAI Life Sciences ( NASDAQ:ATAI ) , icad ( NASDAQ:ICAD ) 6/15/2025 7:51:00 PM
HAPPY FATHER'S DAY and $HARHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger: SVT, SSBK, LNSR, iCAD 6/15/2025 6:29:00 PM
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SVT, LNSR, ICAD, SSBK on Behalf of Shareholders - LENSAR ( NASDAQ:LNSR ) , icad ( NASDAQ:ICAD ) 6/10/2025 11:46:00 AM
$TOCKHOLDER ALERT: The M&A Class Action Firm Encourages Shareholders of SVT, SSBK, LNSR, iCAD to Act 6/9/2025 2:51:00 PM
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LNSR, SWTX, ICAD, SSBK on Behalf of Shareholders - LENSAR ( NASDAQ:LNSR ) , icad ( NASDAQ:ICAD ) 6/4/2025 1:32:00 PM
$HAREHOLDER INVESTIGATION: The M&A Class Action Firm Is Investigating the Merger: SSBK, LNSR, iCAD and BSGM 6/2/2025 11:00:00 PM
Alcon Secures First FDA Approval Since Novartis Spin-Off In 2019 - Alcon ( NYSE:ALC ) 5/29/2025 5:28:00 PM

Financial Details for LNSR

Company Overview

Ticker LNSR
Company Name LENSAR Inc
Country USA
Description LENSAR, Inc. is a commercial-stage medical device company based in Orlando, Florida, that specializes in cutting-edge solutions for ophthalmic surgery, particularly with its flagship femtosecond laser system designed for cataract procedures and corneal astigmatism management. As a pioneer in laser-assisted cataract surgery, LENSAR is positioned to capitalize on the growing demand for innovative ophthalmic technologies, thereby enhancing surgical outcomes and expediting patient recovery. The company is dedicated to continual product development and market expansion, aiming to elevate patient care standards while delivering long-term shareholder value in the evolving ophthalmic industry.
Sector Name HEALTHCARE
Industry Name MEDICAL DEVICES
Most Recent Quarter 6/30/2025
Next Earnings Date 11/6/2025

Stock Price History

Last Day Price 12.30
Price 4 Years Ago 5.99
Last Day Price Updated 10/31/2025 8:47:01 PM EST
Last Day Volume 49,688
Average Daily Volume 45,732
52-Week High 17.31
52-Week Low 5.28
Last Price to 52 Week Low 132.95%

Valuation Measures

Trailing PE N/A
Industry PE 43.83
Sector PE 72.39
5-Year Average PE -14.29
Free Cash Flow Ratio 20.50
Industry Free Cash Flow Ratio 34.08
Sector Free Cash Flow Ratio 28.93
Current Ratio Most Recent Quarter 1.52
Total Cash Per Share 0.60
Book Value Per Share Most Recent Quarter -1.93
Price to Book Ratio 2.17
Industry Price to Book Ratio 3.99
Sector Price to Book Ratio 32.03
Price to Sales Ratio Twelve Trailing Months 2.43
Industry Price to Sales Ratio Twelve Trailing Months 4.49
Sector Price to Sales Ratio Twelve Trailing Months 16.34
Analyst Buy Ratings N/A
Analyst Strong Buy Ratings N/A

Share Statistics

Total Shares Outstanding 11,934,800
Market Capitalization 146,798,040
Institutional Ownership 47.95%

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth -118.34%
Reported EPS 12 Trailing Months -4.21
Reported EPS Past Year -0.21
Reported EPS Prior Year -1.21
Net Income Twelve Trailing Months -49,313,000
Net Income Past Year -31,404,000
Net Income Prior Year -14,383,000
Quarterly Revenue Growth YOY 10.30%
5-Year Revenue Growth 11.87%
Operating Margin Twelve Trailing Months -15.20%

Balance Sheet

Total Cash Most Recent Quarter 7,150,000
Total Cash Past Year 16,263,000
Total Cash Prior Year 20,621,000
Net Cash Position Most Recent Quarter 7,150,000
Net Cash Position Past Year 16,263,000
Long Term Debt Past Year 0
Long Term Debt Prior Year 0
Total Debt Most Recent Quarter 0
Equity to Debt Ratio Past Year 1.00
Equity to Debt Ratio Most Recent Quarter 0.00
Total Stockholder Equity Past Year 4,862,000
Total Stockholder Equity Prior Year 47,176,000
Total Stockholder Equity Most Recent Quarter -9,268,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -5,232,000
Free Cash Flow Per Share Twelve Trailing Months -0.44
Free Cash Flow Past Year -2,431,000
Free Cash Flow Prior Year -9,895,000

Options

Put/Call Ratio 0.00
Has Options Options Chain
Liquidity Rating None

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD -0.09
MACD Signal -0.09
20-Day Bollinger Lower Band 11.69
20-Day Bollinger Middle Band 12.51
20-Day Bollinger Upper Band 13.33
Beta 0.49
RSI 42.88
50-Day SMA 11.79
150-Day SMA 6.35
200-Day SMA 6.27

System

Modified 10/30/2025 3:28:09 AM EST